

Myrna Candelaria

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5018785/publications.pdf>

Version: 2024-02-01

11
papers

246
citations

1163065

8
h-index

1281846

11
g-index

12
all docs

12
docs citations

12
times ranked

410
citing authors

#	ARTICLE	IF	CITATIONS
1	Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial. <i>Annals of Hematology</i> , 2011, 90, 379-387.	1.8	63
2	DNA Methylation-Independent Reversion of Gemcitabine Resistance by Hydralazine in Cervical Cancer Cells. <i>PLoS ONE</i> , 2012, 7, e29181.	2.5	44
3	Comparative assessment of pharmacokinetics, and pharmacodynamics between RTX83, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 515-527.	2.3	31
4	Efficacy of hydralazine and valproate in cutaneous T-cell lymphoma, a phase II study. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 481-487.	4.1	23
5	Rituximab biosimilar RTX83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study. <i>Leukemia and Lymphoma</i> , 2019, 60, 3375-3385.	1.3	22
6	Encouraging results with the compassionate use of hydralazine/valproate (TRANSCRIP) as epigenetic treatment for myelodysplastic syndrome (MDS). <i>Annals of Hematology</i> , 2017, 96, 1825-1832.	1.8	20
7	Real-World Data on Adult T-Cell Leukemia/Lymphoma in Latin America: A Study From the Grupo de Estudio Latinoamericano de Linfoproliferativos. <i>JCO Global Oncology</i> , 2021, 7, 1151-1166.	1.8	15
8	Comparison of Three Chemotherapy Regimens in Elderly Patients with Diffuse Large B Cell Lymphoma: Experience at a Single National Reference Center in Mexico. <i>BioMed Research International</i> , 2016, 2016, 1-10.	1.9	9
9	Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072198957.	2.5	9
10	Clinical characteristics of primary extranodal versus nodal diffuse large B-Cell Lymphoma: A retrospective cohort study in a cancer center. <i>Revista De Investigacion Clinica</i> , 2019, 71, 349-358.	0.4	7
11	A Multi-Institutional Validation of the Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Patients With Diffuse Large B-Cell Lymphoma: A Study From The Latin American Group of Lymphoproliferative Disorders (GELL). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 637-646.	0.4	3